Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer

Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved for use in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Here, we present the cases of two patients with metastatic breast cancer who received T-DM1 monotherapy and developed noncirrho...

Full description

Saved in:
Bibliographic Details
Published in:International cancer conference journal 2020-01, Vol.9 (1), p.18-23
Main Authors: Fujii, Yasutoshi, Doi, Mihoko, Tsukiyama, Naofumi, Hattori, Yui, Ohya, Kazuki, Shiroma, Noriyuki, Morio, Kei, Morioka, Takehiko, Aikata, Hiroshi, Shinozaki, Katsunori, Chayama, Kazuaki
Format: Article
Language:English
Subjects:
Antibodies
Biopsy
Breast cancer
Cancer therapies
Case Report
Chemotherapy
Collagen
Consciousness
Encephalopathy
Epidermal growth factor
Estrogens
Hematemesis
Hepatitis
Hepatotoxicity
Hypertension
Liver cirrhosis
Liver diseases
Mastectomy
Medicine
Medicine & Public Health
Metastases
Metastasis
Monoclonal antibodies
Oncology
Patients
Polymerization
Radiation therapy
Surgical Oncology
Targeted cancer therapy
Tomography
Toxicity
Trastuzumab
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved for use in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Here, we present the cases of two patients with metastatic breast cancer who received T-DM1 monotherapy and developed noncirrhotic portal hypertension (NCPH). Patient 1 presented with ruptured gastric varices at 2 years and 5 months after T-DM1 treatment. Patient 2 presented with intrahepatic portal-hepatic venous shunt at 2 years and 6 months and portal-systemic shunt encephalopathy at 4 years and 11 months after T-DM1 treatment. In both the patients, liver biopsies revealed sinusoidal obstruction syndrome (SOS). T-DM1-induced hepatotoxicity can result from SOS. In long-term administration of T-DM1 the unfavorable events associated with chronic liver circulatory disorder due to SOS, such as NCPH, are concerning.
ISSN:2192-3183
2192-3183
DOI:10.1007/s13691-019-00392-4